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Summary
Introduction: Jugular vein thrombosis is mainly due to infectious, neoplastic and iatrogenic
causes. Activated protein C (APC) resistance is an exceptional cause of jugular vein thrombosis.
Case report: A 40-year-old woman consulted for left lateral neck swelling present for two
weeks. Neck ultrasound revealed left internal jugular vein thrombosis, which was conﬁrmed by
contrast CT. The rest of the examination, including routine clotting assessment and inﬂamma-
tory work-up, was normal. Further investigations demonstrated APC resistance with Factor V
Leiden mutation. Treatment consisted of oral anticoagulants with a good outcome.
Discussion: APC resistance is a recently identiﬁed and relatively frequent cause of throm-
bophilia, mostly due to Factor V Leiden mutation. APC resistance is responsible for 20% to
50% of all thrombotic events. The laboratory diagnosis is based on two tests: a phenotypic test
based on APTT with and without APC and a genotypic test based on detection of a Factor V
Leiden mutation.
Conclusion: Screening for APC resistance and Factor V Leiden mutation is now part of the
aetiological work-up of thromboses, particularly in subjects younger than 50. Treatment is
based on oral anticoagulants.
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Introduction
Internal jugular vein thrombosis is a relatively rare compli-
cation of infection, tumour or head and neck trauma and
can be exceptionally due to haematological disorders. We
report a rare cause of isolated internal jugular vein throm-
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osis, activated protein C (APC) resistance, and describe the
linical features, diagnosis and treatment of APC resistance.
ase report
40-year-old woman with no particular medical history con-
ulted for a left lateral neck swelling present for two weeks.
hysical examination demonstrated a 4 cm, hard, tender and
oorly delimited lateral neck mass underneath the stern-
cleidomastoid muscle. The rest of the ENT and general
xamination was normal. Neck ultrasound showed that the
served.
270 M. Mnejja et al.
F eck:
o
p
t
ﬁ
e
t
m
p
(
n
t
A
o
t
L
u
u
s
c
F
e
D
A
q
1
o
o
o
C
d
e
q
3igure 1 Non-contrast and contrast axial CT scan of the n
paciﬁcation after contrast agent injection.
alpable mass corresponded to left internal jugular vein
hrombosis. Non-contrast and contrast CT of the neck con-
rmed the presence of left internal jugular vein thrombosis
xtending from the origin of the internal jugular vein to the
ransverse sinus (Figs. 1 and 2). The usual clotting assess-
ent, comprising complete blood count, bleeding time,
rothrombin level and activated partial thromboplastin time
APTT), was normal. Protein C and protein S assays were
ormal. Further investigations demonstrated APC resis-
ance reﬂected by a decreased APTT in the presence of
PC/APTT in the absence of APC ratio. No other sites
f thrombosis were identiﬁed. Molecular biology showed
hat the patient was heterozygous for the Factor V (FV)
eiden gene mutation. She was treated with oral anticoag-
lant (Sintrom®) with an INR between 2 and 3. Follow-up
ltrasound examination after three months of treatment
howed revascularization of the jugular vein. Treatment was
ontinued for six months.
igure 2 Contrast axial CT scan of the neck: no contrast
nhancement of the left transverse sinus.
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iscussion
PC resistance is a recently identiﬁed and relatively fre-
uent cause of thrombophilia, described for the ﬁrst time in
993 by Dahlback [1]. It is essentially associated with a risk
f venous thrombosis and, more rarely, pulmonary embolism
r arterial thrombosis [2].
APC resistance is currently responsible for 20% to 50%
f all thrombotic events [3]. It is common among European
aucasian subjects, affecting 15 to 65% of all patients with
eep vein thrombosis, but appears to be uncommon in other
thnic groups [4,5]. APC resistance appears to be fairly fre-
uent in Arab populations with a prevalence of 15% [5] to
0% [6] in patients with venous thrombosis.
APC resistance is a usually hereditary, autosomal domi-
ant abnormality due to a FV mutation [7]. The mutation
ost frequently responsible is a point mutation inducing
ubstitution of the guanine in position 1691 by an ade-
ine in the FV gene, called Leiden mutation [7]. This
utation is detected in 95% of cases [7] and makes
V insensitive to the proteolytic action of APC, result-
ng in thrombophilia. Another mutation associated with
enous thrombosis has also been described: FV Cambridge
3].
APC resistance can also be acquired, secondary to the
resence of antiphospholipid antibodies, use of oral con-
raceptives or thalidomide [8] and paraneoplastic syndrome
9]. Concomitant cancer and FV Leiden is associated with
12-fold increased risk of thrombosis [9]. Paraneoplas-
ic thromboses are recurrent, migratory, and refractory to
reatment and may precede clinical signs of cancer [9]. Con-
equently, all patients with unexplained thrombophlebitis
equire clinical interview and thorough physical examination
ompleted by complementary investigations at the slightest
oubt to avoid missing an occult cancer.
According to the Haute Autorité de la santé (French
ational Authority for Health) [8], APC resistance should be
nvestigated in all patients under 50 with unexplained or
ecurrent deep vein thrombosis and in pregnant women with
eep vein thrombosis or a history of thrombosis, recurrent
iscarriage or intrauterine death [8].
The ﬁrst-line method to detect APC resistance is a clot-
ing method based on APTT with and without APC with a
peciﬁcity of 80% [3]. The APTT in the presence of APC/APTT
tanc
[
[
systematic review of prospective studies. Haematologica
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in the absence of APC ratio is signiﬁcantly decreased in the
case of APC resistance.
Molecular biology screening for FV Leiden mutation can
guide preventive and curative management, as the relative
risk (RR) of thrombosis is 3 to 8 in heterozygous subjects and
80 in homozygous subjects, with a higher risk of recurrence
[10].
Treatment generally consists of long-term oral
anticoagulant therapy [3], which must not exceed six
months for a ﬁrst thrombotic episode [10] except when
the clinical and laboratory setting suggests a risk severe
recurrence [11,12].
Conclusion
APC resistance is a frequent cause of thrombophilia, mostly
due to FV Leiden mutation. It is responsible for 20% to 50%
of all thrombotic events. Screening for APC resistance must
be part of the aetiological work-up of thromboses, particu-
larly in subjects younger than 50. Treatment is based on oral
anticoagulants.
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